Ronan Fougeray

1.4k total citations
50 papers, 818 citations indexed

About

Ronan Fougeray is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ronan Fougeray has authored 50 papers receiving a total of 818 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 21 papers in Surgery and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ronan Fougeray's work include Colorectal Cancer Treatments and Studies (21 papers), Bladder and Urothelial Cancer Treatments (20 papers) and Cancer Treatment and Pharmacology (15 papers). Ronan Fougeray is often cited by papers focused on Colorectal Cancer Treatments and Studies (21 papers), Bladder and Urothelial Cancer Treatments (20 papers) and Cancer Treatment and Pharmacology (15 papers). Ronan Fougeray collaborates with scholars based in France, United States and Italy. Ronan Fougeray's co-authors include Joaquim Bellmunt, Toni K. Choueiri, Yacine Salhi, Jacob Rosenberg, Stéphane Culine, Hans von der Maase, Fabio A.B. Schutz, Eric Winquist, David J. Vaughn and Fabio A. Schutz and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Ronan Fougeray

47 papers receiving 801 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ronan Fougeray France	13	499	498	262	83	70	50	818
Santiago Albiol Spain	11	228 0.5×	336 0.7×	192 0.7×	42 0.5×	182 2.6×	20	608
Estrella M. Carballido United States	12	264 0.5×	185 0.4×	175 0.7×	78 0.9×	120 1.7×	27	499
Jamie C. Riches United States	11	244 0.5×	504 1.0×	221 0.8×	26 0.3×	132 1.9×	26	679
E. Batiste-Alentorn Spain	6	265 0.5×	216 0.4×	170 0.6×	81 1.0×	32 0.5×	11	468
Mitsuhito Sasaki Japan	12	323 0.6×	245 0.5×	129 0.5×	51 0.6×	61 0.9×	52	497
Nataliya Mar United States	13	272 0.5×	298 0.6×	185 0.7×	23 0.3×	104 1.5×	65	588
Méher Ben Abdelghani France	9	334 0.7×	469 0.9×	427 1.6×	44 0.5×	29 0.4×	50	706
Jae Young Joung South Korea	16	355 0.7×	287 0.6×	589 2.2×	23 0.3×	237 3.4×	83	929
Muti Abulafi United Kingdom	19	691 1.4×	404 0.8×	193 0.7×	126 1.5×	112 1.6×	33	908
Iwona Skoneczna Poland	10	192 0.4×	449 0.9×	147 0.6×	20 0.2×	80 1.1×	22	589

Countries citing papers authored by Ronan Fougeray

Since Specialization

Citations

This map shows the geographic impact of Ronan Fougeray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronan Fougeray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronan Fougeray more than expected).

Fields of papers citing papers by Ronan Fougeray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronan Fougeray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronan Fougeray. The network helps show where Ronan Fougeray may publish in the future.

Co-authorship network of co-authors of Ronan Fougeray

This figure shows the co-authorship network connecting the top 25 collaborators of Ronan Fougeray. A scholar is included among the top collaborators of Ronan Fougeray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronan Fougeray. Ronan Fougeray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fougeray, Ronan, et al.. (2024). Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint. Pharmaceutical Statistics. 23(6). 971–983.

Cutsem, Eric Van, Iwona Danielewicz, Mark Saunders, et al.. (2022). First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. British Journal of Cancer. 126(11). 1548–1554. 9 indexed citations

André, Thierry, Alfredo Falcone, Yaroslav Shparyk, et al.. (2022). Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. The Lancet. Gastroenterology & hepatology. 8(2). 133–144. 21 indexed citations

Yoshino, Takayuki, Eric Van Cutsem, Lin Shen, et al.. (2022). Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis. ESMO Open. 7(3). 100511–100511. 8 indexed citations

Bordonaro, Roberto, Aitana Calvo, A. Auriemma, et al.. (2021). Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study. ESMO Open. 6(5). 100270–100270. 11 indexed citations

Argilés, Guillem, Thierry André, Antoine Hollebecque, et al.. (2019). Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. European Journal of Cancer. 112. 12–19. 8 indexed citations

Hollebecque, Antoine, Aitana Calvo, Thierry André, et al.. (2018). Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 36(4_suppl). 816–816. 4 indexed citations

Tabernero, Josep, Eric Van Cutsem, Atsushi Ohtsu, et al.. (2017). QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer. ESMO Open. 2(5). e000284–e000284. 14 indexed citations

Sonpavde, Guru, Gregory R. Pond, Jonathan E. Rosenberg, et al.. (2015). Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 33(15_suppl). 4527–4527. 2 indexed citations

10.

Sonpavde, Guru, Joaquim Bellmunt, Jonathan E. Rosenberg, et al.. (2014). Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 12(6). 395–398. 11 indexed citations

11.

Sonpavde, Guru, Gregory R. Pond, Jonathan E. Rosenberg, et al.. (2014). Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. Clinical Genitourinary Cancer. 13(2). 185–192. 2 indexed citations

12.

Sonpavde, Guru, Joaquim Bellmunt, Jonathan E. Rosenberg, et al.. (2014). Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. Journal of Clinical Oncology. 32(4_suppl). 353–353. 2 indexed citations

13.

Pond, Gregory R., Joaquim Bellmunt, Jonathan E. Rosenberg, et al.. (2014). Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design. Clinical Genitourinary Cancer. 13(1). 71–79. 11 indexed citations

14.

Bellmunt, Joaquim, Ronan Fougeray, Jacob Rosenberg, et al.. (2013). Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Annals of Oncology. 24(6). 1466–1472. 115 indexed citations

15.

Pond, Gregory R., Joaquim Bellmunt, Ronan Fougeray, et al.. (2013). Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design. Clinical Genitourinary Cancer. 11(4). 495–500. 20 indexed citations

16.

Maughan, Benjamin L., Kenneth M. Boucher, Neeraj Agarwal, et al.. (2012). Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 30(15_suppl). 4525–4525. 3 indexed citations

17.

Błasińska-Morawiec, Maria, et al.. (2012). Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer. The Breast. 22(1). 58–63. 7 indexed citations

18.

Maïo, Massimo Di, Maciej Krzakowski, Ronan Fougeray, Dariusz M. Kowalski, & Cesare Gridelli. (2012). Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: External validation in a phase III trial comparing vinflunine with docetaxel. Lung Cancer. 77(1). 116–120. 12 indexed citations

19.

Krajewski, Katherine M., Ronan Fougeray, Joaquim Bellmunt, et al.. (2011). Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. European Journal of Cancer. 48(10). 1495–1502. 17 indexed citations

20.

Nolè, Franco, Diana Crivellari, Rodolfo Mattioli, et al.. (2009). Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 64(4). 673–680. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact